Literature DB >> 2977379

A soluble 'anchorminus' interleukin 2 receptor suppresses in vitro interleukin 2-mediated immune responses.

N Kondo1, S Kondo, A Shimizu, T Honjo, J Hamuro.   

Abstract

The immunosuppressive effects of a recombinant soluble IL-2 receptor L chain (s-IL-2R) were analyzed. S-IL-2R protein was obtained from the conditioned medium of L cells transfected with a mutant cDNA clone encoding the extracytoplasmic portion of the IL-2 receptor (IL-2R) and was purified to homogeneity by an IL-2-coupled sepharose column, following by reverse phase chromatography (HPLC). Soluble IL-2R protein thus prepared retained the ability to bind IL-2 specifically and suppressed the in vitro IL-2-mediated immune responses, including proliferation of IL-2-dependent cell line (CTLL-2), induction of secondary cytotoxic T lymphocytes (CTL) and the mixed lymphocyte reaction (MLR), but did not suppress the growth of IL-3-dependent cell line. Kinetic studies revealed that s-IL-2R exhibited the suppressive effects on the proliferative responses of alloantigen stimulated human tonsillar cells, only when added at an early stage, namely 0-48 h after culture onset, whereas cyclosporin A (CsA) exhibited an inhibitory effect only when added at between 0 and 24 h. This implies that s-IL-2R exerts its effect on an early stage of lymphocyte activation. The observed immunosuppressive effects of s-IL-2R suggest the possibility that s-IL-2R might be useful for the protection of rejection crisis in organ transplantation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2977379     DOI: 10.1016/0165-2478(88)90159-9

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  9 in total

1.  Biological role of the soluble interleukin-2 receptor in sarcoidosis.

Authors:  Remi M M Vanmaris; Ger T Rijkers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus.

Authors:  M Itoh; Y Goto; Y Ohta; Y Goto; H Ohashi
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

3.  Soluble CD8 in patients with rheumatic diseases.

Authors:  J A Symons; N C Wood; F S di Giovine; G W Duff
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

Review 4.  The contribution of interleukin-2 to effective wound healing.

Authors:  Karen M Doersch; Daniel J DelloStritto; M Karen Newell-Rogers
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-25

5.  Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.

Authors:  M A Wasik; N Sioutos; M Tuttle; J R Butmarc; W D Kaplan; M E Kadin
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

6.  The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice.

Authors:  Calliope A Dendrou; Linda S Wicker
Journal:  J Clin Immunol       Date:  2008-09-09       Impact factor: 8.317

7.  Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application.

Authors:  G I Kirchner; A Franzke; J Buer; W Beil; M Probst-Kepper; F Wittke; K Overmann; S Lassmann; R Hoffmann; H Kirchner; A Ganser; J Atzpodien
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

8.  Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins.

Authors:  R Fernandez-Botran; E S Vitetta
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

9.  In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses.

Authors:  D J Deehan; S D Heys; W G Simpson; J Broom; C Franks; O Eremin
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.